Rafee Talukder
@rafee_talukder
Followers
372
Following
901
Media
30
Statuses
310
GU medical oncologist @BCMCancerCenter. Former heme/onc fellow @UWMedicine @fredhutch and IM resident @BCM_InternalMed. All tweets are my own. Proud #Girldad
Houston, TX
Joined May 2016
RT @CParkMD: ⭐️Loved this informative talk by Dr. Hiba Khan @fredhutch . Updated table on the PARP inhibitor combination trials . Also a v….
0
6
0
RT @CParkMD: ⭐️Dr. Scott Tykodi @fredhutch gives a masterful discussion on the only adjuvant study that was positive for RCC. He also gives….
0
6
0
RT @DRBakaloudiMD: I am delighted to share our manuscript evaluating Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in….
0
26
0
RT @CParkMD: ⭐️My good friend @PGrivasMDPhD and I talk about the importance of Mentorship in Oncology. We discuss people we admire such as….
0
19
0
RT @DRBakaloudiMD: Incredibly honored to receive one of the @ConquerCancerFd @ASCO merit awards and be part of this amazing group of brilli….
0
8
0
RT @PGrivasMDPhD: Fantastic talk by @arkhaki #AIBCCR on histology subtypes in #bladdercancer sparking discussion with @h_alahmadie @MattMil….
0
9
0
Excited and honored to have attended my first #BCANTT23. It was truly an amazing experience: got to meet the leaders and rising stars in bladder cancer research and connect with friends, mentors and future collaborators! Looking forward to #BCANTT24!
A great group of #BCANTT23 travel fellows at this year’s meeting! In particular proud of all the work and collaborations with @rafee_talukder @PGrivasMDPhD And proud to be an alum of this group with @arkhaki @ArjunBalarMD and so many others! @bcan_chisolm @BladderCancerUS.
1
5
27
RT @FaltasLab: And here you are the full class of the 2023 #BCANTT23 John Quale Travel fellows
0
2
0
RT @urotoday: Outcomes with immune checkpoint inhibitors in patients with MTAP alterations in advanced #UrothelialCarcinoma. @rafee_talukde….
0
1
0
RT @BladderCancerUS: Congratulations indeed! We are looking forward to seeing everyone at #BCANTT23.
0
1
0
RT @DrRosenbergMSK: Happy to share that EV-103 Cohort K is out in JCO: Enfortumab Vedotin +/- Pembrolizumab in Cisplatin-Ineligible Patient….
ascopubs.org
PURPOSEPatients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for...
0
51
0
Thank you, really enjoyed it!! Best TBT ever!!.
Thank you 🙏🏼for an exceptional & intriguing #TumorBoardTuesday!!. Look for Case Wrap Up🎀Thursday 05/11/23. 🎉Congratulations to @rafee_talukder as he joins @BCMCancerCenter faculty!. 📅Pls mark your calendar Tues 05/16 when @drteplinsky @prarthnavb join to chat using baby Tam
1
1
7
RT @PGrivasMDPhD: Excellent editorial by super mentee @rafee_talukder in relevant topic! @sonpavde @practiceupdate @arkhaki @DRBakaloudiMD….
0
3
0
Promising results with neoadjuvant ipi+nivo in pts with cisplatin-ineligible MIBC. Needs validation with phase II/III studies. Definitely area of unmet need. @sonpavde @PGrivasMDPhD @arkhaki @practiceupdate.
Preoperative high-dose Ipilimumab+Nivolumab appeared active (pCR 43-46%) in muscle-invasive #urothelialcarcinoma-will it improve outcomes as first-line therapy in cisplatin-ineligible advanced disease (CHECKMATE901)-comment @rafee_talukder.@practiceupdate.
1
5
18
RT @PGrivasMDPhD: Fantastic to write this systematic review on enfortumab vedotin with @rafee_talukder @arkhaki @DMakrakisMD we tried to co….
0
3
0
ADCs are so 🔥🔥 right now. Check our systematic review in @touchONCOLOGY on the evolving landscape of enfortumab vedotin in bladder cancer. @PGrivasMDPhD @DMakrakisMD @arkhaki @fredhutch @uwurology @HsiehLab @BCMCancerCenter @bcm_urology @BCAN_Research
0
4
14
Very exciting study! Will "priming" by HDAC inhibitors improve efficacy and response to lutetium Lu 177 (pluvicto) and PSMA ADCs? 🤔🤔🤔.
Proud of our @fredhutch @UW team with Michael Haffner @JessicaHawleyMD @jklee_lab et al. on epigenetic regulation of PSMA expression, nice work that may lead to trial design! .@PCFnews @felixfengmd @HsiehLab @EfstathiouEleni @neerajaiims @rafee_talukder.
0
0
4